|
Market Closed -
Nasdaq
04:00:00 2026-08-26 pm EDT
|
5-day change | 1st Jan Change | ||
| 440.34 USD | -0.43% |
|
-0.46% | +34.53% |
| 04:30am | AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients | MT |
| 03:36am | AstraZeneca and Amgen announce positive Tezspire trial results in EoE | AN |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AMGN Stock
- Consensus Amgen Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
